Literature DB >> 32151633

Dihydroorotate dehydrogenase in oxidative phosphorylation and cancer.

Stepana Boukalova1, Sona Hubackova1, Mirko Milosevic1, Zuzana Ezrova2, Jiri Neuzil3, Jakub Rohlena4.   

Abstract

Dihydroorotate dehydrogenase (DHODH) is an enzyme of the de novo pyrimidine synthesis pathway that provides nucleotides for RNA/DNA synthesis essential for proliferation. In mammalian cells, DHODH is localized in mitochondria, linked to the respiratory chain via the coenzyme Q pool. Here we discuss the role of DHODH in the oxidative phosphorylation system and in the initiation and progression of cancer. We summarize recent findings on DHODH biology, the progress made in the development of new, specific inhibitors of DHODH intended for cancer therapy, and the mechanistic insights into the consequences of DHODH inhibition.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bioenergetics; Cancer; De novo pyrimidine synthesis; Dehydroorotate dehydrogenase; Oxidative phosphorylation

Year:  2020        PMID: 32151633     DOI: 10.1016/j.bbadis.2020.165759

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  15 in total

1.  The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors.

Authors:  Christine R Cuthbertson; Hui Guo; Armita Kyani; Joseph T Madak; Zahra Arabzada; Nouri Neamati
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-23

2.  Prognostic prediction and gene regulation network of EIF2S2 in hepatocellular carcinoma based on data mining.

Authors:  Piyou Ji; Haitao Wang; Yu Cheng; Shaohua Liang
Journal:  J Gastrointest Oncol       Date:  2021-12

3.  Biaryl Compounds as Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia (AML).

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-02-01       Impact factor: 4.345

Review 4.  Investigational antiviral drugs for the treatment of COVID-19 patients.

Authors:  Samineh Beheshtirouy; Elnaz Khani; Sajad Khiali; Taher Entezari-Maleki
Journal:  Arch Virol       Date:  2022-02-09       Impact factor: 2.574

5.  Indazole and Benzoisoxazole Compounds as Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-04-22       Impact factor: 4.632

6.  The Differences of Metabolites in Different Parts of the Brain Induced by Shuxuetong Injection against Cerebral Ischemia-Reperfusion and Its Corresponding Mechanism.

Authors:  Tingyue Jiang; Jiakang Jiao; Jinfeng Shang; Lei Bi; Huanhuan Wang; Chao Zhang; Hongwei Wu; Yiran Cui; Peng Wang; Xin Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-29       Impact factor: 2.650

7.  Development of accelerated high-throughput antiviral screening systems for emerging orthomyxoviruses.

Authors:  Satoko Yamaoka; Carla M Weisend; Vaille A Swenson; Hideki Ebihara
Journal:  Antiviral Res       Date:  2022-03-13       Impact factor: 10.103

8.  Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia (AML).

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-01-11       Impact factor: 4.345

9.  Teriflunomide Preserves Neuronal Activity and Protects Mitochondria in Brain Slices Exposed to Oxidative Stress.

Authors:  Bimala Malla; Agustin Liotta; Helena Bros; Rebecca Ulshöfer; Friedemann Paul; Anja E Hauser; Raluca Niesner; Carmen Infante-Duarte
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

10.  Mitochondrial-Linked De Novo Pyrimidine Biosynthesis Dictates Human T-Cell Proliferation but Not Expression of Effector Molecules.

Authors:  Marlies J W Peeters; Pia Aehnlich; Adriano Pizzella; Kasper Mølgaard; Tina Seremet; Özcan Met; Lene Juel Rasmussen; Per Thor Straten; Claus Desler
Journal:  Front Immunol       Date:  2021-11-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.